Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics

Sage Therapeutics, Inc. (SAGE): $38.48

0.56 (+1.48%)

POWR Rating

Component Grades













Add SAGE to Watchlist
Sign Up

Industry: Biotech



in industry


  • SAGE scores best on the Growth dimension, with a Growth rank ahead of 49.58% of US stocks.
  • SAGE's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • SAGE ranks lowest in Sentiment; there it ranks in the 8th percentile.

SAGE Stock Summary

  • SAGE's price/sales ratio is 349.01; that's higher than the P/S ratio of 99% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for SAGE THERAPEUTICS INC; that's greater than it is for merely 6.77% of US stocks.
  • Revenue growth over the past 12 months for SAGE THERAPEUTICS INC comes in at -99.42%, a number that bests just 0.66% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to SAGE THERAPEUTICS INC, a group of peers worth examining would be CLGN, APLS, CDXS, SPCE, and LXRX.
  • SAGE's SEC filings can be seen here. And to visit SAGE THERAPEUTICS INC's official web site, go to

SAGE Valuation Summary

  • SAGE's price/earnings ratio is -4.4; this is 118.97% lower than that of the median Healthcare stock.
  • Over the past 102 months, SAGE's EV/EBIT ratio has gone up 27.3.

Below are key valuation metrics over time for SAGE.

Stock Date P/S P/B P/E EV/EBIT
SAGE 2022-11-25 347.8 1.6 -4.4 -4.0
SAGE 2022-11-23 344.7 1.6 -4.4 -4.0
SAGE 2022-11-22 342.1 1.6 -4.3 -4.0
SAGE 2022-11-21 322.6 1.5 -4.1 -3.7
SAGE 2022-11-18 331.1 1.6 -4.2 -3.8
SAGE 2022-11-17 322.5 1.5 -4.1 -3.7

SAGE Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 24.77%.
  • The 3 year revenue growth rate now stands at -93.05%.
  • Its 5 year net income to common stockholders growth rate is now at -304.8%.
Over the past 15 months, SAGE's revenue has gone down $1,107,587,000.

The table below shows SAGE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.464 -430.605 -510.35
2022-06-30 6.165 -380.566 -503.198
2022-03-31 6.307 -376.896 -484.183
2021-12-31 6.308 -378.182 -457.892
2021-09-30 1,113.852 730.29 641.715
2021-06-30 1,114.051 708.1 666.151

SAGE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SAGE has a Quality Grade of C, ranking ahead of 62.22% of graded US stocks.
  • SAGE's asset turnover comes in at 0.544 -- ranking 73rd of 681 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SESN are the stocks whose asset turnover ratios are most correlated with SAGE.

The table below shows SAGE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.544 0.999 0.571
2021-06-30 0.637 0.999 0.746
2021-03-31 0.767 0.999 0.960
2020-12-31 0.954 0.999 1.092
2020-09-30 0.008 0.907 -0.813
2020-06-30 0.009 0.929 -0.814

SAGE Price Target

For more insight on analysts targets of SAGE, see our SAGE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.11 Average Broker Recommendation 1.66 (Moderate Buy)

SAGE Stock Price Chart Interactive Chart >

Price chart for SAGE

SAGE Price/Volume Stats

Current price $38.48 52-week high $45.74
Prev. close $37.92 52-week low $27.36
Day low $37.66 Volume 534,200
Day high $38.77 Avg. volume 625,045
50-day MA $37.55 Dividend yield N/A
200-day MA $36.05 Market Cap 2.29B

Sage Therapeutics, Inc. (SAGE) Company Bio

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.

SAGE Latest News Stream

Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream

Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass., November 23, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New York, NY.

Yahoo | November 23, 2022

Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

CAMBRIDGE, Mass., November 22, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET.

Yahoo | November 22, 2022

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Brainsway (BWAY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SAGE Therapeutics (SAGE – Research Report) and Brainsway (BWAY – Research Report). SAGE Therapeutics (SAGE) In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics, with a price target of $50.00. The company's shares closed last Monday at $34.93. According to TipRanks.

Brian Anderson on TipRanks | November 21, 2022

President Barry Greene Just Bought 45% More Shares In Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders (or potential shareholders) will be happy to see that the...

Yahoo | November 17, 2022

Sage Therapeutics (NASDAQ:SAGE) Rises as CEO Loads Up On Stock

Barry E. Greene, CEO, president, and director of Sage Therapeutics (NASDAQ:SAGE), increased his stake in the biopharma company by purchasing 14,500 additional shares on November 10 for a weighted average price of $34.4843. Shares of Sage Therapeutics rallied 7.5% in Tuesday’s extended trading session in reaction to the news. As per an SEC filing, Greene paid a total consideration of nearly $0.5 million for his latest purchase of Sage Therapeutics stock. With this transaction, Greene now holds 46,940 shares of Sage Therapeutics. Generally, purchases by corporate insiders send positive signals to the investors and reflect their confidence in the company's future prospects.

Sirisha Bhogaraju on TipRanks | November 16, 2022

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo 2.18%
3-mo -0.90%
6-mo 4.20%
1-year -1.11%
3-year -75.14%
5-year -58.63%
YTD -9.54%
2021 -50.83%
2020 19.84%
2019 -24.64%
2018 -41.84%
2017 222.58%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.952 seconds.